IRONWOOD PHARMACEUTICALS, INC. Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year
IRONWOOD PHARMACEUTICALS, INC. (IRWD) had Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year of $800.00 thousand as of 2024-09-30, per its 10-Q filed 2024-11-07.
Financial Statements › Notes › Intangible Asset, Finite-Lived, and Capitalized Cost, Software to be Sold, Leased, or Marketed, Estimated Amortization Expense
us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear · last filed 2024-11-07
- 2024-09-30: Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year $800.00K.
- 2024-06-30: Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year $800.00K.
- 2018-06-30: Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year $6.95M.
- 2018-03-31: Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year $10.43M.
| Period end | Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year |
|---|---|
| 2024-09-30 | $800.00K 10-Q · filed 2024-11-07 |
| 2024-06-30 | $800.00K 10-Q · filed 2024-08-08 |
| 2018-06-30 | $6.95M 10-Q · filed 2018-08-06 |
| 2018-03-31 | $10.43M 10-Q · filed 2018-05-04 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Nuvectis Pharma, Inc. (NVCT) | United States | $0.705B | -17.53 |
| Climb Bio, Inc. (CLYM) | United States | $0.683B | -13.03 |
| Verastem, Inc. (VSTM) | United States | $0.706B | -1.71 |
| ZEVRA THERAPEUTICS, INC. (ZVRA) | United States | $0.668B | 14.61 |
| COLLEGIUM PHARMACEUTICAL, INC (COLL) | United States | $0.737B | 24.57 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| Faeth Therapeutics, Inc. (FTH) | United States | $0.750B | |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |